Form 8-K - Current report:
SEC Accession No. 0000950170-21-000231
Filing Date
2021-05-14
Accepted
2021-05-14 08:46:34
Documents
15
Period of Report
2021-05-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20210514.htm   iXBRL 8-K 41350
2 EX-99.1 rare-20210514-ex99_1.htm EX-99.1 32791
3 GRAPHIC img257215797_0.jpg GRAPHIC 375412
4 GRAPHIC img257215797_1.jpg GRAPHIC 375412
  Complete submission text file 0000950170-21-000231.txt   1228613

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20210514.xsd EX-101.SCH 2249
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20210514_lab.xml EX-101.LAB 12931
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20210514_pre.xml EX-101.PRE 9590
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20210514_htm.xml XML 4522
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 21922096
SIC: 2834 Pharmaceutical Preparations